Revance Therapeutics Past Earnings Performance
Past criteria checks 0/6
Revance Therapeutics's earnings have been declining at an average annual rate of -18.5%, while the Pharmaceuticals industry saw earnings growing at 10.5% annually. Revenues have been growing at an average rate of 66% per year.
Key information
-18.5%
Earnings growth rate
-2.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 66.0% |
| Return on equity | n/a |
| Net Margin | -138.4% |
| Next Earnings Update | 09 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Revance Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 234 | -324 | 296 | 0 |
| 30 Sep 23 | 214 | -414 | 278 | 0 |
| 30 Jun 23 | 186 | -358 | 274 | -1 |
| 31 Mar 23 | 157 | -352 | 245 | 0 |
| 31 Dec 22 | 133 | -356 | 224 | 0 |
| 30 Sep 22 | 109 | -274 | 205 | 0 |
| 30 Jun 22 | 99 | -263 | 192 | 10 |
| 31 Mar 22 | 90 | -274 | 195 | 0 |
| 31 Dec 21 | 78 | -281 | 199 | 0 |
| 30 Sep 21 | 63 | -297 | 201 | 0 |
| 30 Jun 21 | 47 | -303 | 197 | 0 |
| 31 Mar 21 | 29 | -292 | 176 | 0 |
| 31 Dec 20 | 15 | -282 | 148 | 0 |
| 30 Sep 20 | 4 | -249 | 125 | 0 |
| 30 Jun 20 | 0 | -209 | 93 | -50 |
| 31 Mar 20 | 0 | -186 | 77 | -24 |
| 31 Dec 19 | 0 | -159 | 62 | 0 |
| 30 Sep 19 | 1 | -155 | 57 | 26 |
| 30 Jun 19 | 3 | -146 | 54 | 97 |
| 31 Mar 19 | 4 | -143 | 53 | 94 |
| 31 Dec 18 | 4 | -143 | 54 | 0 |
| 30 Sep 18 | 3 | -138 | 58 | 83 |
| 30 Jun 18 | 1 | -136 | 53 | 82 |
| 31 Mar 18 | 0 | -128 | 49 | 78 |
| 31 Dec 17 | 0 | -121 | 37 | 80 |
| 30 Sep 17 | 0 | -111 | 38 | 67 |
| 30 Jun 17 | 0 | -99 | 36 | 55 |
| 31 Mar 17 | 0 | -97 | 35 | 52 |
| 31 Dec 16 | 0 | -89 | 34 | 45 |
| 30 Sep 16 | 0 | -85 | 34 | 48 |
| 30 Jun 16 | 0 | -86 | 33 | 50 |
| 31 Mar 16 | 0 | -78 | 32 | 45 |
| 31 Dec 15 | 0 | -73 | 30 | 42 |
| 30 Sep 15 | 0 | -66 | 28 | 37 |
| 30 Jun 15 | 0 | -60 | 28 | 32 |
| 31 Mar 15 | 0 | -57 | 26 | 30 |
| 31 Dec 14 | 0 | -63 | 24 | 28 |
| 30 Sep 14 | 1 | -49 | 22 | 26 |
| 30 Jun 14 | 1 | -48 | 18 | 24 |
| 31 Mar 14 | 1 | -38 | 17 | 23 |
| 31 Dec 13 | 1 | 0 | 15 | 23 |
| 30 Sep 13 | 0 | -10 | 10 | 38 |
Quality Earnings: RTI is currently unprofitable.
Growing Profit Margin: RTI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RTI is unprofitable, and losses have increased over the past 5 years at a rate of 18.5% per year.
Accelerating Growth: Unable to compare RTI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RTI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.6%).
Return on Equity
High ROE: RTI's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.